Summary
78 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 68% a year over the last 3 years.
- It holds more cash than debt: ¥11.3B against ¥5.71B.
- It earns 17 JPY a year on every 100 JPY of invested capital.
- Analysts expect revenue to grow by 15% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.3 JPY for 1 JPY of yearly profit. Over the last five years it was 52.6 JPY on average.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 15%. Earnings per share grew by 68% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 23 JPY
- Sales and administration 67 JPY
- Taxes and other 3.3 JPY
- Net profit 7.0 JPY
Net profit, industry median (Medical - Instruments & Supplies) 8.1 JPY
Out of every 100 JPY of revenue, 7.0 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.11%
- Paid out of profit
- 34%
- Raised in a row
- 2 years
You receive $0.73 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.